Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

Sponsor

Avobis Bio, LLC (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04847739

Collaborator

Alimentiv Inc. (Other)

Enrollment

Locations

Arms

39.6

Anticipated Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A Phase II study to assess the safety and efficacy of AVB-114 in treatment of complex Crohn's perianal fistulas in subjects with quiescent rectal disease and whose fistula has failed to respond to biologic or conventional therapy. Combined remission of treated perianal fistula in the investigational treatment arm will be compared to a standard of care control arm.

The study has 2 parts:

Part 1: All required study visits for subjects who initially receive study treatment and those who receive standard of care therapy (control arm).

Part 2: Subjects who are enrolled in the control arm may receive treatment with AVB-114 following week 36. Those subjects then will be followed as specified in the clinical protocol.

Condition or Disease	Intervention/Treatment	Phase
Perianal Fistula Crohn's Disease	Procedure: Seton Placement Drug: AVB-114	Phase 2

Detailed Description

AVB-114 is an investigational therapy which offers a new therapeutic approach to treating this unmet medical need. The drug product is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

Actual Study Start Date :

Sep 13, 2021

Anticipated Primary Completion Date :

Aug 1, 2023

Anticipated Study Completion Date :

Jan 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Standard of Care Treatment + AVB-114 Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.	Procedure: Seton Placement This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable. Drug: AVB-114 AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
Active Comparator: Standard of Care Treatment Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.	Procedure: Seton Placement This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.

Arm

Intervention/Treatment

Experimental: Standard of Care Treatment + AVB-114

Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.

Procedure: Seton Placement

This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.

Drug: AVB-114

AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.

Active Comparator: Standard of Care Treatment

Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.

Procedure: Seton Placement

Outcome Measures

Primary Outcome Measures

Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups. [36 weeks]

Secondary Outcome Measures

Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups. [Week 12 to Week 104]
Change in the means of durability of clinical remission between the AVB-114 and standard of care groups. [Week 12 to Week 104]
Length of time fistula meets clinical remission definition.
Change in means of time to clinical remission between the AVB-114 and standard of care groups. [Week 12 to Week 104]
Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups. [Week 12 to Week 104]
Change in means of time to fistula relapse between the AVB-114 and standard of care groups. [Week 12 to Week 104]
Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups. [Baseline, Week 12 to Week 52]
Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups. [Baseline, Week 36]
Perianal Disease Activity Index (PDAI). Possible scores range from 0-20, with a higher score indicating more severe perianal disease activity
Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups. [Baseline, Week 36]
Short Crohn's Disease Activity Index (sCDAI). Possible scores range from 44 to >450, with a higher score representing more severe disease activity
Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups. [Baseline, Week 36]
Euroqol 5 Dimension 5, level measure of health status (EQ-5D-5L). The scale ranges in scores from 0 to 100, with a higher score indicating a more severe health status.
Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups. [Baseline, Week 36]
Inflammatory Bowel Disease Questionnaire (IBDQ). Possible scores range from 32-224, with a higher score indicating a better health-related quality of life.
Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups. [Baseline, Week 12 to Week 36]
Days of missed work or activity and reason why will be captured.
Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups. [Week 12 to Week 36]
Number and type of healthcare resources utilized will be captured.
Change in number of adverse events between the AVB-114 and standard of care groups. [Day 1 to Week 104]
Change in number of serious adverse events between the AVB-114 and standard of care groups. [Day 1 to Week 104]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of signed and dated ICF.
Ability and willingness to comply with study protocol and study requirements for the duration of the study.
Male or female, 18-70 years of age
Subjects with CD diagnosed at least 6 months prior to screening visit.
Subjects with a single fistula tract with one internal opening and one external opening, including a previously performed conversion of a branching fistula tract to a single fistula tract where the branching occurred outside the sphincter complex.
Subjects whose perianal fistula(s) were previously treated with either biologic or conventional therapy whose fistula has demonstrated a failed response or who have documented medication intolerance.
Women of childbearing potential (WCBP) must have negative serum pregnancy test at screening (sensitive to 25 IU human chorionic gonadotropin). WCBP participating in this study must agree to use an adequate method of contraception during the entire duration of the study. Males who have sexual partners that are women of childbearing potential must be willing to use a barrier method for contraception for the duration of study.

Exclusion Criteria:

Clinically significant medical conditions within the six months before screening that would, in the opinion of the investigator, compromise the safety of the subject with study participation and/or the ability of the subject to follow study protocol.
Evidence of hepatitis B, C, or HIV or subjects with congenital or acquired immunodeficiencies.
Participation in an investigational drug study (within 30 days of last administration from screening visit) or investigational medical device study (within 1 year of implant from screening visit) where investigational treatment (drug or device) is placed in rectum, vagina, or near fistula location, or that may potentially interact with study treatment.
History (within previous 5 years of screening visit) of invasive cancer including melanoma (with the exception of localized skin cancers).
Subjects pregnant, trying to become pregnant, or are breast feeding.
Subjects with contraindications to Magnetic Resonance (MR) evaluations and/or to MR contrast.
History of clinically significant fat-directed autoimmunity.
Concomitant recto-vaginal fistula
Concomitant ileal anal pouch perineal fistulas.
Active, unresolved infection requiring parenteral antibiotics.
Any major surgery of the gastrointestinal tract (including one or more segments of the colon or terminal ileum) within 3 months prior to screening visit. Presence of stoma is not exclusionary.
Subjects who had a definitive surgical procedure for the target fistula or a perianal procedure that resulted in a large soft tissue defect within 6 months prior to screening visit.
A compromised abdominal region due to a previous cool sculpting procedure, abdominal radiation, chemotherapy, recent tattoos, local infection, or other reasons that may compromise the adipose tissue for study use.
Subjects previously treated with Cx601/Alofisel or other allogeneic or autologous stem-cell therapy within the past 6 months.
Contraindications to the anesthetic procedure (local and general) or to the adipose tissue collection procedure.
Subjects with one or more of the following fistula types or anatomic presentations:
Horseshoe fistulas
Fistulas that do not have an opening inside the anal canal or low rectum
Blind ending sinus tracts (no external opening)
Branching fistulas that involve or are near the sphincter complex and cannot be converted to single tracts without risk to injury to the sphincter complex
1 internal opening
Moderate or severe proctitis
Severe rectal mucosal fibrosis surrounding the internal opening preventing the securing of the fistula plug cap.
Any anatomical limitation to successfully securing the fistula plug cap
Evidence by colonoscopy of moderately or greater active luminal CD.
Subject with ongoing systemic or rectal steroids for CD in the last 2 weeks prior to screening and baseline study visits.
History of, or concurrent high-grade dysplasia, adenocarcinoma, and carcinoma in situ on colonoscopy within 5 years of screening visit.
Subjects with renal insufficiency (creatinine value > 1.8 mg/dL, eGFR < 44, or patient undergoing dialysis).
Subjects with a hemoglobin less than 8 gm/dL.
Subjects with serum aspartate transaminase (AST) or alanine transaminase (ALT) > 2 times the upper limit of normal (ULN).
Subjects with undrained peri-anal sepsis.
Subjects with known coagulopathy (abnormal INR) or thrombocytopenia as indicated by a platelet count < 75,000.
Subjects with history of substance abuse (drug or alcohol) that would interfere with the ability to comply with the study protocol and study requirements.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic	Scottsdale	Arizona	United States	85259
2	Office of Phillip Fleshner, MD	Los Angeles	California	United States	90048
3	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
4	Mayo Clinic	Rochester	Minnesota	United States	55905
5	Vanderbuilt University Medical Center Diagnostic Laboratory	Nashville	Tennessee	United States	37204